Novo Holdings to Finalize $16.5B Acquisition of Catalent Following Regulatory Clearance

Acquisition Agreement:
Novo Holdings, a global life sciences investment firm, has entered into an agreement to acquire Catalent, a leading provider of drug delivery technologies and pharmaceutical development solutions, for $16.5 billion135.

Regulatory Clearance:
The transaction has cleared all regulatory hurdles, including antitrust approvals, and is expected to close in the coming days23.

Post-Close Transactions:
Novo Holdings intends to sell three of Catalent’s fill-finish manufacturing sites located in Anagni, Italy; Bloomington, Indiana, USA; and Brussels, Belgium to Novo Nordisk, a pharmaceutical company focused on developing treatments for chronic conditions135.

Strategic Fit:
The acquisition aligns with Novo Holdings’ strategy of investing in established life science companies with strong long-term potential135.

Benefits:
Under private ownership, Catalent will benefit from access to additional capital and resources to enhance service offerings for the benefit of customers and patients135.

Shareholder Approval:
Catalent stockholders voted to approve the pending transaction in May 202415.

Transaction Details:
The acquisition is an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis, with Catalent stockholders receiving $63.50 per share in cash15.

Sources:

1. https://transaction.catalent.com

2. https://www.fiercepharma.com/pharma/fda-clears-novos-wegovy-shortage-list-marking-end-semaglutide-supply-rout-us

3. https://www.worldpharmaceuticals.net/news/catalent-and-novo-holdings-to-finalise-acquisition-following-regulatory-clearance/

5. https://www.catalent.com/catalent-news/novo-holdings-to-acquire-catalent/